- May 21
- 6 min read
Updated: Jul 14
Key TakeawaysBCMA-targeted CAR-T for relapsed/refractory multiple myeloma has shown overall response rates exceeding 80%, with some cohorts reporting 80–90% and select patients reaching MRD-negative remission — though CAR-T is not considered a guaranteed cure, and relapse can still occur. Two BCMA-targeted CAR-T products are named as approved or widely studied in China — Equecabtagene autoleucel (CT053) and Ciltacabtagene autoleucel — both indicated for relapsed or refractory multiple myeloma. Commercial CAR-T in China runs roughly 60–70% less than U.S. pricing, where total cost — including hospitalization and ICU care — can exceed $500,000–$1 million. Some Chinese platforms report manufacturing turnaround as fast as 24–36 hours, versus several weeks under traditional systems, contributing to faster "vein-to-vein" timelines for eligible patients. ChinaCureLink (a Medebound HEALTH company, 10+ years, 3,000+ patients) guides international patients from first case submission through treatment and follow-up for advanced myeloma care in China. |
For patients with relapsed or refractory multiple Myeloma, CAR-T cell therapy has become one of the most important advances in modern blood cancer treatment.
And increasingly, international patients are looking toward China.
Why?
Because China now combines:
Large-scale CAR-T manufacturing capacity
Multiple approved BCMA-targeted CAR-T products
Faster treatment timelines
Extensive clinical trial access
Significantly lower costs than the U.S. and Europe
In 2026, China is considered one of the world’s largest and most active CAR-T treatment ecosystems.
Table of Contents |
What Is CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an advanced form of immunotherapy where:
A patient’s own T-cells are collected
The cells are genetically engineered in a lab
They are reprogrammed to recognize cancer cells
The modified cells are infused back into the patient
For multiple myeloma, most CAR-T therapies target:
BCMA (B-cell maturation antigen)
This protein is commonly expressed on malignant plasma cells.
Unlike chemotherapy, CAR-T is often described as a “living drug” because the engineered immune cells can continue attacking cancer after infusion.
Why China Has Become a Major CAR-T Destination
China has rapidly expanded its cellular therapy infrastructure over the last several years.
The country now has:
Multiple NMPA-approved CAR-T products
Hundreds of active CAR-T clinical trials
Large specialized hematology centers
Domestic manufacturing platforms that reduce production times
Some Chinese centers now report manufacturing timelines as short as 24–36 hours, compared with several weeks in traditional systems.
China is also considered one of the global leaders in next-generation CAR-T innovation, including:
Dual-target CAR-T
Fast-manufacture platforms
Relapse-resistant designs
Solid tumor CAR-T research
CAR-T Therapy in China for Multiple Myeloma
The strongest CAR-T activity in multiple myeloma currently focuses on:
Relapsed/refractory disease
Patients who failed multiple prior therapies
Patients resistant to proteasome inhibitors, IMiDs, or anti-CD38 therapy
Several BCMA-targeted products are now approved or widely studied in China.
Approved BCMA CAR-T Products
As of 2026, China has approved multiple CAR-T therapies for multiple myeloma, including:
Equecabtagene autoleucel (CT053)
Ciltacabtagene autoleucel (Carvykti-related platform)
These therapies are indicated for relapsed or refractory multiple myeloma.
Reported Outcomes
Published and conference-reported data from Chinese CAR-T programs have shown:
Overall response rates often exceeding 80%
Deep remission responses in heavily pretreated patients
MRD-negative responses in selected cases
Some international reviews report response rates in multiple myeloma CAR-T programs reaching 80–90% in certain cohorts.
However, outcomes vary substantially depending on:
Disease burden
Prior treatments
Cytogenetic risk
Patient fitness
CAR-T platform used
Importantly:CAR-T is not considered a guaranteed cure for multiple myeloma, and relapse can still occur.
Country Comparison (2026)
CAR-T therapy in China costs roughly $100,000–$150,000 in total, compared with $500,000–$700,000 in the United States — about 70–85% less, using NMPA-approved products at leading hospitals.
🇺🇸 United States | 🇨🇳 China | |
Total cost of care | $500,000 – $700,000 | $100,000 – $150,000 |
Typical / median | ~$608,100 | ≈70–85% lower |
What's included | Drug, hospitalization, CRS/ICANS management, supportive care, follow-up | Drug, hospital stay, cell manufacturing, monitoring, follow-up |
Drug price alone | $373,000 – $475,000 (before hospital costs) | Bundled into total |
Approved products | 6 (FDA) | 7 (NMPA) |
Manufacturing time | 3–5 weeks | 24 hrs – 2 weeks at leading centers |
Time on-site | Local | ~6–10 weeks (incl. monitoring) |
Indicative ranges based on 2025–2026 published data and ChinaCureLInk case coordination. Final quotes depend on diagnosis, product, hospital, and length of stay. Not medical or financial advice.
Why Is CAR-T Cheaper in China?
Lower pricing is largely driven by:
Domestic biotech manufacturing
Reduced supply chain costs
High-volume production systems
Government-supported biotechnology investment
Faster manufacturing platforms
Importantly, lower cost does not automatically mean lower quality.
Several Chinese CAR-T products use similar biological targets and engineering concepts as Western-approved therapies.
Clinical Trials in China
China currently operates one of the world’s largest CAR-T clinical trial networks.
International patients may sometimes qualify for:
Investigator-Initiated Trials (IITs)
Expanded-access protocols
Next-generation CAR-T studies
These pathways may dramatically reduce treatment cost if eligibility criteria are met.
Areas under active investigation include:
Dual-target BCMA CAR-T
BCMA + CD19 CAR-T
Faster-manufacture CAR-T
Reduced toxicity designs
Post-CAR-T relapse strategies
Major Risks and Side Effects
CAR-T therapy is extremely powerful — but it can also be dangerous.
Cytokine Release Syndrome (CRS)
This immune overactivation syndrome can cause:
High fever
Low blood pressure
Organ dysfunction
ICU admission
Neurotoxicity (ICANS)
Potential symptoms include:
Confusion
Seizures
Speech problems
Neurological impairment
Prolonged Immune Suppression
Patients may experience:
Severe infections
Low blood counts
Long-term immune vulnerability
This is why CAR-T should only be performed at experienced specialized centers.
Treatment Timeline
Some fast-manufacturing Chinese platforms now report dramatically shorter “vein-to-vein” times.
Who May Be Eligible?
Eligibility usually depends on:
Confirmed multiple myeloma diagnosis
Relapsed or refractory disease
Prior treatment history
Organ function
Performance status
Infection status
Bone marrow reserve
Patients with severe frailty or uncontrolled infection may not qualify.
China vs U.S. CAR-T Access
China’s rapid expansion in cellular therapy infrastructure has made it one of the most closely watched CAR-T environments globally.
Important Considerations for International Patients
Patients considering CAR-T in China should carefully verify:
Hospital accreditation
Physician expertise
Trial legitimacy
Regulatory oversight
ICU capabilities
Long-term follow-up planning
Not all clinics advertising “cell therapy” are legitimate CAR-T centers.
Patients should also understand:
CAR-T can involve life-threatening complications
Long-term remission is not guaranteed
Follow-up care after returning home is essential
FAQ: Frequently Asked Questions:
Why are patients traveling to China for CAR-T?
The main reasons include:
Lower cost
Faster access
Expanded clinical trial availability
Access to next-generation CAR-T platforms
Final Thoughts
CAR-T therapy has dramatically changed the treatment landscape for relapsed and refractory multiple myeloma. What was once considered untreatable disease progression can now, in some patients, be pushed into deep remission through advanced cellular immunotherapy.
China has emerged as one of the world’s most active CAR-T treatment hubs because of its:
Rapid biotech expansion
Large clinical trial ecosystem
Faster manufacturing infrastructure
More accessible pricing
For international patients facing limited access, long waitlists, or unaffordable costs in their home countries, China may offer a realistic pathway to advanced CAR-T treatment.
At the same time, CAR-T remains one of the most complex and medically intensive therapies in oncology. It requires:
Careful patient selection
Experienced multidisciplinary teams
Advanced ICU support
Long-term follow-up planning
The decision to pursue CAR-T therapy abroad should always involve detailed medical review, realistic expectations, and careful evaluation of the treating institution.
As global cell therapy technology continues advancing, China is likely to remain at the center of next-generation CAR-T innovation for multiple myeloma and other hematologic cancers.
Refrences
1. Equecabtagene Autoleucel (Fucaso; CT103A): First Approval — Molecular Diagnosis & Therapy (Springer), 2023. https://link.springer.com/article/10.1007/s40291-023-00673-y
2. Phase II Study of Zevorcabtagene Autoleucel (zevor-cel; CT053), a Fully Human BCMA-Targeting CAR T-Cell Therapy in r/r Multiple Myeloma — Experimental Hematology & Oncology / PMC, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12482220/
3. Next-Day Manufacture of a Novel Anti-CD19 CAR-T Therapy (FasT CAR-T): First-in-Human Study — Blood Cancer Journal (Nature), 2022. https://www.nature.com/articles/s41408-022-00694-6
4. A Global Multidimensional Analysis of the CAR-T Clinical Trial Landscape — Biomarker Research (Springer), 2026. https://link.springer.com/article/10.1186/s40364-026-00910-6
5. Costs of Care During CAR-T Therapy in r/r B-Cell Lymphomas (US total-cost benchmark) — JNCI Cancer Spectrum (Oxford), 2024. https://academic.oup.com/jncics/article/8/4/pkae059/7730013
6. Gilead's Kite Exits China Cell Therapy JV with Fosun Pharma (Yescarta China list price ¥1.2M ≈ US$170K) — FiercePharma, 2024. https://www.fiercepharma.com/pharma/gileads-kite-exits-china-cell-therapy-jv-fosun-pharma
About ChinaCurelink
ChinaCurelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCurelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
Comments